Last Thursday 24 February the ICBCC Policy Strategy Working Group met to discuss on the Policy Strategy to address the specific impact of the pandemic on immunocompromised blood cancer patients (both acute and chronic) in a workshop-style setting. The meeting was facilitated by our partner Patvocates. During the 2 hour workshop the group managed to define...Continue Reading
The primary analysis of the ICARIA-MM study showed significant improvement in progression-free survival with addition of isatuximab to pomalidomide–dexamethasone in relapsed and refractory multiple myeloma. Here, we report a prespecified updated overall survival analysis at 24 months after the primary analysis. Methods In this randomised, multicentre, open-label, phase 3 study adult patients (aged ≥18 years) with relapsed...Continue Reading
Isatuximab continues to show promise as a standard of care therapy for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitors, according to a two-year, follow-up analysis of the ICARIA-MM study However the CD38-directed monoclonal antibody may find it difficult to make its mark in the Australian setting any time soon. The study, published...Continue Reading
